ArticleMedicine2026
Baseline predictors of early progression during EGFR-TKI therapy in patients with EGFR-mutant non-small cell lung cancer: A retrospective cohort study.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This single-center retrospective cohort study investigated baseline clinical, molecular, and treatment-related factors associated with early progression among patients with epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer receiving EGFR tyrosine kinase inhibitors (EGFR-TKIs) between June 2022 and June 2025. Eligible patients treated during the study period were consecutively screened according to predefined eligibility criteria, and all eligible patients were included without case-control matching. Early progression was defined a priori as progressive disease within 6 months after EGFR-TKI initiation according to response evaluation criteria in solid tumors version 1.1; this cutoff was selected as a clinically meaningful landmark for early treatment failure/primary resistance and to distinguish rapid failure from patients achieving at least short-term disease control. A total of 156 patients were included (early progression, n = 52; nonearly progression, n = 104). Compared with nonearly progression, early progression was characterized by a different smoking distribution, lower body mass index, higher prevalence of chronic obstructive pulmonary disease, and greater baseline tumor burden as reflected by a higher number of target lesions, as well as higher rates of liver metastasis, bone metastasis, and pleural effusion. Molecular and treatment profiling showed higher frequencies of TP53 co-mutation and baseline EGFR T790M in early progressors, together with a higher proportion of first-generation EGFR-TKI use and more frequent receipt of EGFR-TKI as second-line or later therapy. In multivariable logistic regression, current smoking, lower body mass index, higher target lesion count, liver metastasis, bone metastasis, pleural effusion, second-line or later EGFR-TKI use, first-generation EGFR-TKI exposure, and mesenchymal-epithelial transition factor amplification were independently associated with early progression, while baseline EGFR T790M showed a borderline association. These findings support risk-adapted monitoring and molecularly informed management strategies in EGFR-mutant non-small cell lung cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.